Humana
HUM
$378.88
-0.49%
Humana Inc. is a leading managed healthcare company, primarily offering Medicare Advantage, Medicaid, and military health insurance plans, along with complementary services such as pharmacy benefit management and primary care through its CenterWell segment. As one of the largest private health insurers in the U.S., Humana has carved out a distinct niche in government-sponsored programs, which account for nearly all of its medical membership. The current investor narrative centers on the company's strong recovery from a challenging 2025, driven by favorable Medicare Advantage payment rate increases from CMS, a robust first-quarter 2026 earnings report, and a strategic focus on integrating healthcare services to improve margins and member outcomes. The stock has surged over 38% in the past year, reflecting renewed confidence in its growth trajectory and operational execution.…
HUM
Humana
$378.88
Related headlines
Investment Opinion: Should I buy HUM Today?
Based on the analysis, HUM is rated a Buy, supported by strong revenue growth of 23.47% YoY, a robust earnings rebound with Q1 EPS of $9.85, and a favorable Medicare policy environment. The analyst consensus is Buy with an average target of $416.43, implying a 7.04% upside, while the high target of $513 suggests potential for 31.9% gains. The forward PE of 23.48x is below the trailing PE, indicating expected earnings growth of ~10.5%, which supports the growth thesis.
Sign up to view all
HUM 12-Month Price Forecast
The AI assessment is bullish on HUM, driven by strong revenue acceleration, a solid earnings rebound, and supportive policy tailwinds. The valuation is reasonable relative to growth, and analyst sentiment is positive. However, the medium confidence reflects the risks of regulatory changes and margin volatility. If the company continues to deliver strong results and margins improve, the stance would be upgraded to high confidence. Conversely, any signs of margin compression or policy headwinds would lead to a downgrade to neutral.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Humana's 12-month outlook, with a consensus price target around $416.43 and implied upside of +9.9% versus the current price.
Average Target
$416.43
0 analysts
Implied Upside
+9.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$280 - $513
Analyst target range
The target price range spans from a low of $280.00 to a high of $513.00, indicating a wide dispersion of expectations. The high target of $513 assumes continued strong execution, favorable Medicare policy, and potential multiple expansion, while the low target of $280 suggests concerns about regulatory changes, competitive pressures, or margin compression. Recent ratings actions show a mix of holds and upgrades, with Wells Fargo upgrading to Overweight in July 2026, while Morgan Stanley maintains an Underweight stance, highlighting divergent views on the stock's future performance.
Bulls vs Bears: HUM Investment Factors
Humana presents a compelling bull case driven by accelerating revenue growth, a strong earnings rebound, and favorable Medicare policy tailwinds. The stock has rewarded investors with a 111% six-month rally, reflecting renewed confidence in its execution. However, the elevated valuation (PE 25.95x) and thin margins (net margin 0.92%) introduce significant downside risk if growth falters or costs rise. The most critical tension is whether Humana can sustain its growth trajectory and margin improvement to justify the premium multiple, or if regulatory changes or competitive pressures will compress earnings. Currently, the bull case has stronger evidence given the robust Q1 results and policy support, but investors must monitor execution closely.
Bullish
- Revenue Growth Accelerating: Q1 2026 revenue surged 23.47% YoY to $39.65 billion, driven by strong Medicare Advantage membership and favorable rate adjustments. This marks a significant acceleration from prior quarters, indicating robust demand and effective execution.
- Strong Earnings Rebound: Q1 2026 EPS of $9.85 swung from a loss of $6.61 in Q4 2025, reflecting a sharp recovery in profitability. Net income of $1.19 billion demonstrates the company's ability to overcome prior headwinds and capitalize on improved Medicare rates.
- Favorable Medicare Policy Tailwind: CMS announced a larger-than-expected 2027 Medicare Advantage payment increase, boosting revenue visibility across the sector. This policy tailwind directly benefits Humana, which derives nearly all its medical membership from government programs.
- Analyst Consensus: Buy: With 23 analysts, the consensus rating is 'Buy' with a mean score of 2.19 (1=Strong Buy, 5=Sell). The average target price of $416.43 implies a 7.04% upside from the current price of $389.05, reflecting broad optimism.
Bearish
- Elevated Valuation vs. History: The trailing PE of 25.95x is well above the 5-year average of ~17x for Humana, indicating the market is pricing in sustained growth. This premium leaves little room for disappointment, as any earnings miss could trigger a sharp de-rating.
- Thin Profit Margins: Net margin is only 0.92% and operating margin is 1.12%, reflecting the low-margin nature of the insurance business. Even small cost overruns or adverse medical claims can significantly impact profitability, as seen in the Q4 2025 loss.
- Regulatory and Policy Risk: Humana's heavy reliance on Medicare Advantage makes it vulnerable to changes in government reimbursement rates. While the 2027 increase was favorable, future cuts or policy shifts could compress margins and reduce growth prospects.
- High Debt-to-Equity Ratio: The debt-to-equity ratio of 0.73 indicates a moderate but notable leverage level. With interest expenses of $193 million in Q1 2026, rising interest rates could pressure earnings and limit financial flexibility.
HUM Technical Analysis
Humana's stock has exhibited a powerful uptrend over the past year, with a 1-year price change of +38.28%, significantly outperforming the S&P 500's +20.37% gain. The current price of $389.05 sits at approximately 90.7% of its 52-week range (between $163.11 and $428.88), indicating the stock is trading near its highs, which typically signals strong momentum but also potential overextension. The 6-month price change of +111.33% underscores the magnitude of the rally, placing the stock in a firmly bullish long-term trend.
Beta
0.74
0.74x market volatility
Max Drawdown
-47.5%
Largest decline past year
52-Week Range
$163-$429
Price range past year
Annual Return
+28.7%
Cumulative gain past year
| Period | HUM Return | S&P 500 |
|---|---|---|
| 1m | -4.7% | +2.5% |
| 3m | +23.0% | +2.7% |
| 6m | +99.6% | +11.1% |
| 1y | +28.7% | +20.5% |
| ytd | +43.3% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HUM Fundamental Analysis
Humana's revenue trajectory has been robust, with Q1 2026 revenue of $39.65 billion, representing a 23.47% year-over-year growth rate, a significant acceleration from the prior year's quarters. The Insurance segment contributed $38.06 billion, while the CenterWell segment added $6.1 billion, highlighting the diversified revenue streams. This growth is driven by strong Medicare Advantage membership and favorable rate adjustments, positioning the company for continued expansion.
Quarterly Revenue
$39.6B
2026-03
Revenue YoY Growth
+23.5%
YoY Comparison
Gross Margin
15.0%
Latest Quarter
Free Cash Flow
$1.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HUM Overvalued?
Given Humana's positive net income, the price-to-earnings (PE) ratio is the most appropriate valuation metric. The trailing PE stands at 25.95x, while the forward PE is 23.48x, indicating that the market expects earnings growth of approximately 10.5% over the next year. This forward discount suggests a positive growth outlook, as investors are paying less for future earnings relative to current levels.
PE
26.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 4x~24x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include a high debt-to-equity ratio of 0.73, which could strain cash flows if interest rates rise, especially with $193 million in quarterly interest expenses. The company's thin net margin of 0.92% leaves little buffer for cost overruns or medical claim surprises, as evidenced by the Q4 2025 loss of $796 million. Additionally, free cash flow of $1.27 billion TTM is modest relative to revenue, limiting financial flexibility for investments or dividends. Revenue concentration in Medicare Advantage is a key financial risk, as any adverse policy change could directly impact the top line and profitability.